# South Korea Brucellosis Market > South Korea Brucellosis Market Research Report By species (Brucella suis, B. abortus, B. melitensis) -Forecast to 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.15% - **2024:** $ 19.73 Million - **2025:** $ 21.14 Million - **2035:** $ 42.16 Million - **Key Players:** Zoetis (US), Merck & Co (US), Boehringer Ingelheim (DE), Ceva Santé Animale (FR), Heska Corporation (US), Virbac (FR), Vetoquinol (FR), IDT Biologika (DE) **Report ID:** MRFR/LS/51828-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-brucellosis-market-53589 --- ## Market Summary ## **South Korea Brucellosis Market Overview** As per MRFR analysis, the South Korea Brucellosis Market Size was estimated at 7.12 (USD Million) in 2023.The South Korea Brucellosis Market is expected to grow from 7.75(USD Million) in 2024 to 19.37 (USD Million) by 2035. The South Korea Brucellosis Market CAGR (growth rate) is expected to be around 8.684% during the forecast period (2025 - 2035). **Key South Korea Brucellosis Market Trends Highlighted** Growing awareness of animal health and food safety issues is driving significant changes in the brucellosis market in South Korea. In an effort to reduce contagious diseases, the government has enacted stronger laws governing disease prevention and animal management. Investments in animal and human vaccines and diagnostics have resulted from the increased emphasis on brucellosis prevention strategies brought about by the growth of dairy and cattle production. This highlights the convergence of the veterinary and human health domains and represents a trend toward integrated disease management techniques that incorporate public health. There are new opportunities in the market, especially in the areas of diagnostic testing and vaccine development. As the world moves toward more effective and efficient disease management, South Korea's focus on cutting-edge biotechnology research and technology provides a path for creative ways to fight brucellosis. Furthermore, public-private collaborations offer an advantageous setting for improving research on brucellosis, which could result in quicker development cycles and better access to state-of-the-art technologies. Public education initiatives to raise knowledge of brucellosis prevention and transmission have also increased recently, according to trends. By enabling farmers to adopt better methods, increased access to information through a variety of media platforms has helped to lower the incidence of brucellosis. These instructional efforts are further supported by the incorporation of technology into farming methods, such as the use of data-driven approaches for animal health monitoring. All things considered, the South Korean market is developing quickly, successfully combating brucellosis by fusing technology breakthroughs with stable regulations. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South Korea Brucellosis Market Drivers** **Increasing Awareness and Education about Brucellosis** In South Korea, there has been a significant push towards increasing awareness and education regarding brucellosis, particularly among farmers and livestock owners. Initiatives from the Ministry of Agriculture, Food and Rural Affairs have focused on educating stakeholders about the prevention and control of zoonotic diseases like brucellosis. This is critical, as brucellosis can lead to substantial economic losses in livestock. According to government reports, there has been a 35% increase in the number of outreach programs focused on zoonotic diseases since 2019. Furthermore, the Korean Animal Health Association plays a vital role in disseminating information and resources, which directly contributes to the growth of the South Korea [Brucellosis Market](../../../reports/brucellosis-market-5159). The heightened awareness not only leads to better practices in livestock management but also encourages the use of diagnostic tests and vaccines, thus driving market growth. **Technological Advancements in Diagnostic Methods** Technological advancements in the development of diagnostic tests for brucellosis have significantly bolstered the South Korea Brucellosis Market. Innovations in laboratory methods, such as polymerase chain reaction (PCR) tests and enzyme-linked immunosorbent assay (ELISA), have provided more efficient and accurate detection of the disease. As reported by the Korean Journal of Veterinary Research, the implementation of rapid diagnostic tests has reduced testing time by up to 50%, enabling quicker responses to outbreaks. This advancement not only aids in controlling the disease spread but also encourages farmers and veterinarians to adopt more proactive measures in disease management, thus enhancing demand for diagnostic products in the market. **Government Policy Support and Investment** The South Korean government has been actively investing in policies aimed at controlling outbreaks of brucellosis, which are expected to positively influence the South Korea Brucellosis Market. The recent enactment of the Livestock Health and Protection Act aims to strengthen biosecurity measures and veterinary services across the nation. According to government publications, the budget for veterinary services has increased by 20% in the last fiscal year alone, enabling better disease surveillance and response mechanisms. Such government initiatives not only enhance the capacity for disease control but also increase the market appeal for diagnostic and veterinary products related to brucellosis, thus driving overall market growth. **South Korea Brucellosis Market Segment Insights** **Brucellosis Market species Insights** The South Korea Brucellosis Market, particularly within the species segment, is characterized by significant diversity and complex dynamics. Brucella suis, primarily associated with pigs, presents a noteworthy challenge in ensuring animal health and food safety, given the increasing consumption of pork in South Korea. The importance of B. suis stretches beyond immediate health concerns, as its management is critical for the agricultural economy and trade relations, particularly with major agricultural producers. B. abortus, known for affecting cattle, plays a crucial role in the dairy and beef industry, where its prevalence can lead to substantial economic losses, thus driving demand for effective management strategies. The presence of B. melitensis, primarily linked to sheep and goats, adds another layer to the market, as it is known for its zoonotic potential, posing risks to human health through consumption and occupational exposure. This species, due to its ability to survive in various environments and affect a wider range of hosts, emphasizes the need for comprehensive surveillance and control programs. The South Korea government's initiatives reflect an awareness of these challenges and the necessity of robust biosecurity measures to mitigate risks. With evolving agricultural practices and increasing interconnectivity in trade, the importance of understanding these particular species in the context of South Korea's agricultural landscape cannot be overstated. Market growth in this segment will largely hinge on advancements in diagnostic methods, vaccination programs, and public awareness campaigns aimed at both animal and human health, as effective handling of these species ensures sustainable agricultural practices and consumer safety. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South Korea Brucellosis Market Key Players and Competitive Insights** The South Korea Brucellosis Market has been characterized by an increasing focus on infectious diseases, particularly zoonotic infections like brucellosis, prompting heightened efforts from both public and private sectors to address this health concern. Competitive dynamics in this market reflect a blend of innovative research, product development, and strategic partnerships aimed at preventing and treating brucellosis effectively. With its high prevalence among livestock and subsequent risk to human health, the market landscape is shaped by key players who contribute to the development of vaccines, diagnostic tools, and therapeutic options. The interplay of regulatory policies, technological advancements, and the growing awareness about brucellosis among healthcare professionals and the agricultural sector further delineates the competitive environment in South Korea. Medytox has established a strong position within the South Korea Brucellosis Market, recognized for its commitment to advancing research and providing high-quality solutions for brucellosis management. The company's strengths lie in its well-established research and development capabilities, which allow it to create innovative products tailored to the specific needs of the South Korean healthcare landscape. Medytox leverages its deep understanding of local epidemiological conditions and strong relationships with both government bodies and healthcare institutions to facilitate the adoption of its products. This strategic approach ensures that Medytox remains a pivotal player in the market, addressing both preventive and therapeutic challenges posed by brucellosis through its expertise and locally relevant offerings. SK Chemicals also plays a significant role in the South Korea Brucellosis Market, focusing on the development of vaccines and diagnostic kits that enhance disease management efforts. The company is known for its strong research orientation and has built a solid foundation in biopharmaceutical products, including those targeting infectious diseases. SK Chemicals excels in leveraging its extensive distribution network to ensure that its products reach a wide customer base, thereby maximizing its market presence. In addition to its core offerings, the company is actively involved in collaborations and partnerships that enhance its product portfolio and strengthen its competitive edge. SK Chemicals' emphasis on innovation is further illustrated through strategic mergers and acquisitions which facilitate access to new technologies and market segments, solidifying its stance in addressing the challenges associated with brucellosis in South Korea. **Key Companies in the South Korea Brucellosis Market Include** - Medytox - SK Chemicals - CJ CheilJedang - Osang Healthcare - Samsung Biologics - Korea United Pharm - Celltrion - Korea Vaccine - Green Cross Corporation - Pharmbio - Genexine - Hugel - LG Chem - Hanmi Pharmaceutical - Daewoong Pharmaceutical **South Korea Brucellosis****Market****Developments** The South Korea Brucellosis Market has witnessed several notable developments recently. In October 2023, the Ministry of Agriculture, Food and Rural Affairs of South Korea announced heightened surveillance of animal health to combat rising cases of brucellosis among livestock, specifically focusing on cattle and swine. This initiative aims to mitigate risks associated with zoonotic transmission to humans. Key companies in this sector such as Medytox, SK Chemicals, and Green Cross Corporation are actively engaging in Research and Development to enhance vaccine production and improve diagnostic methods for brucellosis. In terms of mergers and acquisitions, Celltrion has notably expanded its portfolio with an acquisition of a smaller biotechnology firm specializing in infectious diseases in September 2023, further strengthening its capabilities in biopharmaceuticals. Additionally, major firms like CJ CheilJedang and Samsung Biologics continue to invest in innovative solutions to bolster their market presence. The market is experiencing growth in valuation driven by advances in vaccine technology and increased public health initiatives targeting brucellosis, as well as efforts from the Korea Vaccine and Hanmi Pharmaceutical in vaccine development over the past few years. **South Korea Brucellosis Market Segmentation Insights** **Brucellosis Market species Outlook** - Brucella suis - B. abortus - B. melitensis ## Market Drivers ### Rising Livestock Trade The brucellosis market is also influenced by the rising livestock trade in South Korea. As the demand for meat and dairy products continues to grow, the movement of livestock across regions has increased. This trend, while beneficial for the economy, poses challenges for disease management, including brucellosis. The government is likely to invest in monitoring and control measures to ensure that livestock trade does not contribute to the spread of the disease. The livestock sector's contribution to the national economy is substantial, with estimates suggesting it accounts for around 5% of the agricultural GDP. Consequently, the brucellosis market may see a surge in demand for diagnostic tools and vaccines to manage the health of traded animals, thereby enhancing market growth. ### Enhanced Veterinary Regulations The brucellosis market in South Korea is experiencing a notable shift due to enhanced veterinary regulations. The government has implemented stricter guidelines for livestock management, which aim to reduce the incidence of brucellosis among cattle and other livestock. This regulatory framework not only promotes animal health but also safeguards public health by minimizing the risk of zoonotic transmission. As a result, the market is likely to see an increase in demand for veterinary services and products aimed at disease prevention. The financial implications are significant, with the veterinary services sector projected to grow by approximately 10% annually, reflecting the increasing focus on disease control in livestock. This trend indicates a robust future for the brucellosis market, driven by regulatory compliance and enhanced veterinary practices. ### Increased Public Health Awareness Increased public health awareness regarding zoonotic diseases is another driver impacting the brucellosis market. As consumers become more informed about the risks associated with animal diseases, there is a growing demand for transparency in food production and safety. This trend is prompting livestock producers to adopt better health management practices, which in turn influences the market for brucellosis-related products and services. The public's heightened concern about food safety is likely to lead to increased investments in disease prevention measures, including vaccination and testing. This shift in consumer behavior could result in a market growth rate of approximately 7% over the next few years, as stakeholders respond to the demand for safer food products. ### Technological Advancements in Vaccination Technological advancements in vaccination are playing a crucial role in shaping the brucellosis market. Innovative vaccine development is leading to more effective and safer options for livestock, which is essential for controlling brucellosis outbreaks. The introduction of new vaccines that provide longer-lasting immunity could potentially reduce the incidence of the disease significantly. Furthermore, the South Korean government is likely to support research and development initiatives in this area, recognizing the economic impact of livestock diseases. The market for veterinary vaccines is projected to grow at a CAGR of 8% over the next five years, indicating a strong potential for the brucellosis market as vaccination becomes a cornerstone of disease prevention strategies. ### Collaboration Between Public and Private Sectors Collaboration between public and private sectors is emerging as a significant driver for the brucellosis market. Partnerships between government agencies, research institutions, and private companies are fostering innovation in disease management and prevention strategies. These collaborations are likely to enhance the development of effective diagnostic tools and vaccines, which are critical for controlling brucellosis outbreaks. The South Korean government is expected to allocate funding for joint initiatives aimed at improving livestock health and reducing disease prevalence. This collaborative approach could lead to a more resilient livestock sector, with the potential to increase market opportunities in the brucellosis market by an estimated 6% in the coming years. ## Future Outlook The [Brucellosis Market](https://www.marketresearchfuture.com/reports/brucellosis-market-5159) in South Korea is projected to grow at a 7.15% CAGR from 2025 to 2035, driven by increased awareness and advancements in diagnostic technologies. **New opportunities:** - Development of mobile diagnostic units for remote testing - Investment in vaccine research for livestock - Partnerships with agricultural cooperatives for awareness campaigns By 2035, the market is expected to achieve substantial growth and enhanced disease management capabilities. ## Segment Insights ### By Species: Brucella abortus (Largest) vs. Brucella suis (Fastest-Growing) In the South Korea brucellosis market, the distribution of market share among various species reveals that Brucella abortus occupies the largest segment due to its prevalence in livestock and the associated economic impact. Brucella suis follows closely, showcasing significant traction among emerging markets and veterinary practices. Other species such as Brucella melitensis and Brucella canis have smaller shares but are critical in niche applications, contributing to the diversity of the market. The growth trends in this segment are primarily driven by increased awareness and testing among livestock producers regarding brucellosis. The emergence of Brucella suis as the fastest-growing species is indicative of changing agricultural practices and rising veterinary services. Enhanced control measures and government initiatives to manage and prevent brucellosis outbreaks further support this growth, emphasizing the need for effective solutions in the market. Brucella abortus (Dominant) vs. Brucella suis (Emerging) Brucella abortus stands as the dominant player in the South Korea brucellosis market due to its significant impact on cattle health and livestock economics. It is primarily associated with bovine brucellosis, causing severe losses in dairy and meat production. Efforts to curb its spread have led to increased vaccination and testing protocols among farms. On the other hand, Brucella suis, traditionally impacting pig populations, is emerging as a notable concern owing to changing farming practices and the ecological balance between livestock and wildlife. Its rising prevalence in veterinary focus highlights a shift towards newer approaches in disease management, providing opportunities for innovative solutions and market participation. ### By Diagnosis: Serological Tests (Largest) vs. Molecular Techniques (Fastest-Growing) In the South Korea brucellosis market, serological tests encompass a substantial portion of the diagnostic methods, holding the largest market share due to their widespread availability and ability to quickly detect antibodies in patients. In contrast, molecular techniques, which involve advanced methods such as PCR, are emerging rapidly, gaining traction because of their specificity and sensitivity in detecting the brucella pathogen in diverse specimens. Growth trends in this segment are being driven by several factors, including increased awareness of brucellosis and its implications, improvements in laboratory technology, and the rising focus on precision medicine. Additionally, the increasing prevalence of brucellosis in both livestock and humans encourages innovation and investment in more accurate diagnostic tools, which bodes well for the future expansion of molecular techniques in the market. Serological Tests (Dominant) vs. Bone Marrow Biopsy (Emerging) Serological tests play a dominant role in the South Korea brucellosis market due to their effectiveness in large-scale screening and quick turnaround times. These tests are often the first line of diagnosis and are valued for their non-invasive nature. Conversely, bone marrow biopsy represents an emerging but crucial diagnostic method, utilized when serological tests yield inconclusive results. This method, although more invasive, offers significant insights into the presence of brucella organisms, especially in chronic cases. As the focus on accurate and early diagnosis intensifies, the role of bone marrow biopsy is likely to expand, complementing traditional serological approaches and enhancing overall diagnostic accuracy. ### By Treatment: Antibiotics (Largest) vs. Vaccines (Fastest-Growing) In the South Korea brucellosis market, the treatment segment is predominantly characterized by antibiotics, holding a significant market share. This segment has been pivotal in managing brucellosis outbreaks, with several established products available. Vaccines are emerging as a critical component in disease prevention, showing rapid growth due to increased awareness and vaccination initiatives. The growth trends in the treatment segment are primarily driven by advancements in antibiotic formulations and the rising acceptance of vaccines among both veterinarians and livestock owners. As awareness of brucellosis impacts on agricultural productivity increases, the demand for effective treatment and preventive solutions is likely to grow. Additionally, initiatives focusing on public health and food safety are further propelling the adoption of vaccines, indicating a shift towards more preventive measures in managing the disease. Antibiotics: Established (Dominant) vs. Vaccines (Emerging) Antibiotics have an established position in the South Korea brucellosis market, characterized by well-recognized efficacy in treating infected animals. These products are widely utilized due to their reliable performance in reducing infection rates. On the other hand, vaccines are emerging as a vital tool in the prevention landscape, aimed at safeguarding livestock before the onset of disease. The growing acceptance of vaccines, coupled with innovative product development, is enhancing their market presence. While antibiotics dominate in treatment scenarios, vaccines are gaining traction, signifying a shift towards a more balanced approach in managing brucellosis, which may soon redefine treatment paradigms. ### By End-User: Hospitals & Diagnostic Centers (Largest) vs. Academic Institutes (Fastest-Growing) In the South Korea brucellosis market, hospitals & diagnostic centers hold the largest market share, driven by the increasing demand for early diagnosis and treatment of brucellosis. This segment accounts for significant healthcare resources, including specialized diagnostics and treatment protocols. Academic institutes, on the other hand, represent a rapidly growing segment, fueled by ongoing research and development in brucellosis and increased educational initiatives aimed at understanding the disease better. Growth trends indicate a rising focus on brucellosis in clinical research and diagnostics, primarily due to heightened awareness of zoonotic diseases. The collaboration between pharmaceutical & biotechnology companies and hospitals enhances the potential for innovations in treatment options. Furthermore, government initiatives and funding for research in brucellosis accelerate developments, particularly within academic institutions, making them a vital part of the ecosystem in the South Korea brucellosis market. Hospitals & Diagnostic Centers (Dominant) vs. Academic Institutes (Emerging) Hospitals & diagnostic centers are considered the dominant players in the South Korea brucellosis market due to their extensive infrastructure and established protocols for diagnosing and managing the disease. These facilities are crucial for providing timely care and leveraging advanced technologies for accurate detection. In contrast, academic institutes serve as emerging contributors, primarily focused on research, education, and the development of more effective treatment methodologies. Their role is becoming increasingly significant as they collaborate with healthcare providers to translate research findings into clinical practice, thus enhancing overall disease management and educating emerging professionals in the field. ## Competitive Benchmarking The brucellosis market exhibits a competitive landscape characterized by a blend of established players and emerging innovators. Key growth drivers include increasing awareness of zoonotic diseases, advancements in diagnostic technologies, and a rising demand for effective vaccines. Major companies such as Zoetis (US), Merck & Co (US), and Boehringer Ingelheim (DE) are strategically positioned to leverage these trends. Zoetis (US) focuses on innovation in vaccine development, while Merck & Co (US) emphasizes partnerships to enhance its product portfolio. Boehringer Ingelheim (DE) is investing in regional expansion, particularly in Asia, to capture growing market opportunities. Collectively, these strategies shape a competitive environment that is increasingly dynamic and responsive to market needs.Key business tactics within the brucellosis market include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several key players exerting influence over specific segments. This fragmentation allows for niche players to thrive, while larger companies consolidate their positions through strategic acquisitions and partnerships, thereby enhancing their market share and operational capabilities. In October Zoetis (US) announced the launch of a new brucellosis vaccine aimed at improving livestock health and productivity. This strategic move is significant as it not only reinforces Zoetis's commitment to innovation but also addresses the growing demand for effective disease management solutions in the agricultural sector. The introduction of this vaccine is likely to enhance the company's competitive edge in the market. In September Merck & Co (US) entered into a collaborative agreement with a leading agricultural research institute to develop advanced diagnostic tools for brucellosis. This partnership is pivotal as it underscores Merck's strategy to integrate cutting-edge technology into its offerings, thereby enhancing its diagnostic capabilities. Such collaborations may lead to improved disease detection and management, positioning Merck favorably against its competitors. In August Boehringer Ingelheim (DE) expanded its production facility in South Korea to increase the output of its brucellosis vaccine. This expansion reflects the company's commitment to meeting the rising demand in the region and signifies a strategic investment in local manufacturing capabilities. By enhancing production capacity, Boehringer Ingelheim is likely to strengthen its market presence and improve supply chain reliability. As of November current competitive trends in the brucellosis market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in product development and diagnostics. Strategic alliances are shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on technological advancements, innovative solutions, and robust supply chain management. This transition may ultimately enhance the resilience and adaptability of companies operating within the market. ## Recent News & Developments The South Korea Brucellosis Market has witnessed several notable developments recently. In October 2023, the Ministry of Agriculture, Food and Rural Affairs of South Korea announced heightened surveillance of animal health to combat rising cases of brucellosis among livestock, specifically focusing on cattle and swine. This initiative aims to mitigate risks associated with zoonotic transmission to humans. Key companies in this sector such as Medytox, SK Chemicals, and Green Cross Corporation are actively engaging in Research and Development to enhance vaccine production and improve diagnostic methods for brucellosis. In terms of mergers and acquisitions, Celltrion has notably expanded its portfolio with an acquisition of a smaller biotechnology firm specializing in infectious diseases in September 2023, further strengthening its capabilities in biopharmaceuticals. Additionally, major firms like CJ CheilJedang and Samsung Biologics continue to invest in innovative solutions to bolster their market presence. The market is experiencing growth in valuation driven by advances in vaccine technology and increased public health initiatives targeting brucellosis, as well as efforts from the Korea Vaccine and Hanmi Pharmaceutical in vaccine development over the past few years. ## Report Scope | MARKET SIZE 2024 | 19.73(USD Million) | | --- | --- | | MARKET SIZE 2025 | 21.14(USD Million) | | MARKET SIZE 2035 | 42.16(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.15% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Zoetis (US), Merck & Co (US), Boehringer Ingelheim (DE), Ceva Santé Animale (FR), Heska Corporation (US), Virbac (FR), Vetoquinol (FR), IDT Biologika (DE) | | Segments Covered | Species, Diagnosis, Treatment, End-User | | Key Market Opportunities | Emerging diagnostic technologies enhance detection and management of brucellosis in livestock and humans. | | Key Market Dynamics | Rising regulatory scrutiny and technological advancements drive innovation in brucellosis diagnostics and treatment solutions. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What was the overall market valuation for brucellosis in South Korea in 2024?** A: The overall market valuation for brucellosis in South Korea was $19.73 Million in 2024. **Q: What is the projected market valuation for brucellosis in South Korea by 2035?** A: The projected market valuation for brucellosis in South Korea is $42.16 Million by 2035. **Q: What is the expected CAGR for the South Korea brucellosis market during the forecast period 2025 - 2035?** A: The expected CAGR for the South Korea brucellosis market during the forecast period 2025 - 2035 is 7.15%. **Q: Which companies are considered key players in the South Korea brucellosis market?** A: Key players in the South Korea brucellosis market include Zoetis, Merck & Co, Boehringer Ingelheim, Ceva Santé Animale, Heska Corporation, Virbac, Vetoquinol, and IDT Biologika. **Q: What are the main segments of the South Korea brucellosis market?** A: The main segments of the South Korea brucellosis market include species, diagnosis, treatment, and end-user. **Q: What was the valuation of the Brucella melitensis segment in 2024?** A: The valuation of the Brucella melitensis segment was $4.0 Million in 2024. **Q: What is the projected valuation for the antibiotics treatment segment by 2035?** A: The projected valuation for the antibiotics treatment segment is $12.56 Million by 2035. **Q: How much is the serological tests segment expected to grow by 2035?** A: The serological tests segment is expected to grow to $7.5 Million by 2035. **Q: What is the valuation range for the hospitals & diagnostic centers end-user segment in 2024?** A: The valuation range for the hospitals & diagnostic centers end-user segment was $7.5 Million to $15.5 Million in 2024. **Q: What is the projected growth for the Brucella canis segment by 2035?** A: The projected growth for the Brucella canis segment is expected to reach $4.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-brucellosis-market-53589*